Reversible effects on female rat fertility with abrocitinib, a Janus kinase 1 inhibitor

Background Abrocitinib is a Janus kinase (JAK) 1 selective inhibitor approved for the treatment of atopic dermatitis. Female reproductive tissues were unaffected in general toxicity studies, but an initial female rat fertility study resulted in adverse effects at all doses evaluated. A second rat fe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Birth defects research 2024-05, Vol.116 (5), p.e2345-n/a
Hauptverfasser:	Bowman, Christopher J., Campion, Sarah N., Catlin, Natasha R., Nowland, William S., Stethem, Christine M., Radi, Zaher A., Cappon, Gregg D.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Atopic dermatitis Cohabitation Dermatitis Embryo Implantation - drug effects Embryos Enzyme inhibitors Female female fertility female reproduction Females Fertility Fertility - drug effects Implantation JAK1 Janus kinase Janus Kinase 1 - antagonists & inhibitors Janus Kinase 1 - metabolism Janus Kinase Inhibitors - pharmacology Kinases Pregnancy Pregnancy Rate Pyrimidines - pharmacology Rats Rats, Sprague-Dawley Recovery reversibility Sulfonamides - pharmacology Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!